Glenn A. Eisenberg Sells 8,400 Shares of Laboratory Corp. of America Holdings (LH) Stock

Laboratory Corp. of America Holdings (NYSE:LH) CFO Glenn A. Eisenberg sold 8,400 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $167.36, for a total value of $1,405,824.00. Following the completion of the transaction, the chief financial officer now owns 15,931 shares of the company’s stock, valued at approximately $2,666,212.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Laboratory Corp. of America Holdings (NYSE LH) traded up $1.07 during trading hours on Wednesday, reaching $172.08. The company’s stock had a trading volume of 264,920 shares, compared to its average volume of 651,748. The stock has a market capitalization of $17,152.28, a PE ratio of 14.13, a price-to-earnings-growth ratio of 1.48 and a beta of 0.93. Laboratory Corp. of America Holdings has a 1-year low of $134.10 and a 1-year high of $181.71. The company has a quick ratio of 1.20, a current ratio of 1.31 and a debt-to-equity ratio of 0.93.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.07. The business had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.70 billion. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The firm’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.15 earnings per share. sell-side analysts predict that Laboratory Corp. of America Holdings will post 11.53 EPS for the current fiscal year.

LH has been the subject of a number of research analyst reports. Robert W. Baird set a $183.00 target price on Laboratory Corp. of America and gave the company a “hold” rating in a research note on Thursday, February 8th. Zacks Investment Research cut Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Barclays restated a “buy” rating and issued a $195.00 target price on shares of Laboratory Corp. of America in a research note on Wednesday, December 13th. Craig Hallum restated a “buy” rating and issued a $180.00 target price (up previously from $175.00) on shares of Laboratory Corp. of America in a research note on Thursday, October 26th. Finally, Jefferies Group restated a “hold” rating and issued a $170.00 target price on shares of Laboratory Corp. of America in a research note on Friday, October 20th. Six research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $180.73.

A number of large investors have recently made changes to their positions in LH. Guggenheim Capital LLC increased its holdings in shares of Laboratory Corp. of America by 3.9% in the 4th quarter. Guggenheim Capital LLC now owns 283,331 shares of the medical research company’s stock worth $45,193,000 after purchasing an additional 10,696 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Laboratory Corp. of America by 11.5% in the 4th quarter. Deutsche Bank AG now owns 473,335 shares of the medical research company’s stock worth $75,497,000 after purchasing an additional 48,981 shares in the last quarter. Brandywine Global Investment Management LLC increased its holdings in shares of Laboratory Corp. of America by 3.2% in the 4th quarter. Brandywine Global Investment Management LLC now owns 92,618 shares of the medical research company’s stock worth $14,774,000 after purchasing an additional 2,878 shares in the last quarter. Jefferies Group LLC increased its holdings in shares of Laboratory Corp. of America by 660.2% in the 4th quarter. Jefferies Group LLC now owns 36,818 shares of the medical research company’s stock worth $5,873,000 after purchasing an additional 31,975 shares in the last quarter. Finally, Advisor Group Inc. increased its holdings in shares of Laboratory Corp. of America by 32.0% in the 4th quarter. Advisor Group Inc. now owns 6,326 shares of the medical research company’s stock worth $1,010,000 after purchasing an additional 1,532 shares in the last quarter. Institutional investors and hedge funds own 91.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Glenn A. Eisenberg Sells 8,400 Shares of Laboratory Corp. of America Holdings (LH) Stock” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/14/glenn-a-eisenberg-sells-8400-shares-of-laboratory-corp-of-america-holdings-lh-stock.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply